Eslicarbazepine Acetate Description

Eslicarbazepine acetate (ESL) is an anticonvulsant medication accustomed for use in Europe, the United States and Canada as an accessory test for partial-onset seizures that are not abundantly controlled with accepted therapy. Eslicarbazepine acetate is a prodrug that is rapidly adapted to eslicarbazepine, the primary alive metabolite in the body. Eslicarbazepine's apparatus of action is not able-bodied understood, but it is accepted that it does apply anticonvulsant action by inhibiting again neuronal battlefront and stabilizing the inactivated accompaniment of voltage-gated sodium channels, appropriately preventing their acknowledgment to the activated accompaniment during which access action can occur.

Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is accessible in 200, 400, 600, or 800mg tablets that are taken already daily, with or after food. Eslicarbazepine acetate is associated with abundant ancillary furnishings including dizziness, drowsiness, nausea, vomiting, diarrhea, headache, aphasia, abridgement of concentration, psychomotor retardation, accent disturbances, ataxia, abasement and hyponatremia. It is recommended that patients demography eslicarbazepine acetate be monitored for suicidality.